TX-CIRRUS-LOGIC
25.6.2024 15:01:32 CEST | Business Wire | Press release
Cirrus Logic (Nasdaq: CRUS) today unveiled the latest devices in its Pro Audio product family: a series of digital-to-analog converters (DACs) and an ultra-high performance audio CODEC that set a new standard for the prosumer and professional audio markets. These new solutions cater to the needs of recording artists, live performers, and audiophiles, delivering transparent audio converters to ensure recording and playback without any compromise in sound quality.
This launch expands on last year's successful analog-to-digital converters (ADCs) launch. Crafted with a focus on superior analog functionality and digital integration, these devices from Cirrus Logic offer exceptional performance, minimal power requirements, and innovative features like hybrid gain control, addressing longstanding audio challenges in the industry.
“True transparency in audio—that’s the hallmark of Cirrus Logic’s Pro Audio Family. It’s not just about sound, it’s about the authenticity from creation to consumption. Our commitment is purity in audio reproduction, ensuring that what you hear is as true to the original as possible,” said Eddie Sinnott, Director of Product Marketing. “With this new series of flagship audio products, we’re setting a gold standard for both professionals and prosumers, enabling our customers to create distinctive products with the confidence of our world-class engineering and support.”
Cirrus Logic CS4308P/CS4304P/CS4302P DACs and CS4282P CODEC
Designed with ease of use in mind, the Cirrus Logic Pro Audio 8-channel DAC CS4308P, 4-channel CS4304P, 2-channel CS4302P and CODEC CS4282P seamlessly integrate within a wide range of audio equipment. These new devices offer configurable advanced digital filters allowing our customers to define their signature sound. Cirrus Logic designs the devices with users in mind, making them as simple as possible to integrate and extract their full potential.
“As a long-time user of Cirrus Logic, we are excited about the new additions to its family of DAC and CODEC products being launched today,” said Simon Jones, CTO, Focusrite Group. “Cirrus Logic’s desire to keep setting the benchmark in audio quality is evident. These devices are designed to flawlessly integrate with a diverse spectrum of audio equipment, from USB audio interfaces to professional speakers and musical instruments. The addition of a hybrid gain control system into the CODEC and new ADC’s is a game changer for system integration that we really appreciate. At Focusrite, crafting audio interfaces is not just our business; it’s our passion. We bridge the gap between the artist and the audience, ensuring the sound conveyed is pristine.”
Exceptional Efficiency with Leading-Edge performance
The Pro Audio family also offers industry-leading power efficiency at 10 mW/ch for the 8/4-channel DACs, underlining Cirrus Logic’s longstanding commitment to bringing energy-efficient products to market. These new devices are 32-bit offering sample rates of up to 768 kHz, providing 129 dB of dynamic range for the CS4302P/CS4282P and 123 dB for the CS4304/8P. THD+N for these devices are all -114 dB or lower.
Product Availability
Samples of the CS4304/8P DACs and the CS4282P are available to order now. The converters are controllable and configurable using Cirrus Logic’s SoundClear® Studio software, which is available at www.cirrus.com. Samples of the CS4302P DAC will follow, later in the year.
Cirrus Logic Inc.
Cirrus Logic is a leader in low-power, high-precision mixed-signal processing solutions that create innovative user experiences for the world’s top mobile and consumer applications. With headquarters in Austin, Texas, Cirrus Logic is recognized globally for its award-winning corporate culture. Check us out at www.cirrus.com.
Cirrus Logic, Cirrus and the Cirrus Logic logo are registered trademarks of Cirrus Logic, Inc. All other company or product names noted herein may be trademarks of their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625199957/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 10:00:00 CEST | Press release
Gabriele Salvatores, together with Rob Minkoff, Catherine Hardwicke, Jed Weintrob, Christina Lee Storm, Nils Hartmann, Guillem Martinez Roura, Filippo Rizzante, Giacomo Mineo, Brian Welk and Denise Negri, will judge the short films in competition based on creativity, production quality and the use of Artificial Intelligence. Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, wh
Bregal Milestone Announces Majority Growth Investment in CoreGo, a Leading European Open-Loop Payment and Event Technology Company29.4.2026 10:00:00 CEST | Press release
Investment follows over 98% annual growth and supports CoreGo’s continued market expansion Bregal Milestone, a leading European software growth private equity firm, today announced a majority strategic growth investment in CoreGo Oy ("CoreGo" or the "Company"), a leading provider of open-loop payments and integrated technology solutions for festivals, sports events, and venues across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427991105/en/ Founded in Helsinki in 2015 by Hannu Elomaa and CTO Nikoteemu Väänänen, CoreGo has built one of Europe's most differentiated open-loop payment infrastructure and event technology businesses. Serving approximately 250 customers across the Nordics and DACH region, the Company delivers an integrated showtime-critical suite of solutions through CoreGo Cloud, unifying payments, access, networks, and data into a single real-time operating system. CoreGo’s in-house private network
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
